Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
NCT ID: NCT04961515
Last Updated: 2025-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
19 participants
INTERVENTIONAL
2021-07-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
NCT04899427
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
NCT04231370
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT07077512
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
NCT00385125
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
NCT05209620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will receive fixed-dose orelabrutinib, sintilimab, and temozolomide for up to six 21-day cycles (induction phase), followed by sintilimab maintenance until disease progression (PD), intolerable toxicity, investigator/patient decision to withdraw, or a maximum treatment duration of 2 years (whichever occurs first). Tumor response will be assessed by MRI every two cycles during induction and every three months thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OST regimen
Participants will receive:
1. Orelabrutinib: 150 mg orally once daily;
2. Sintilimab: 200 mg intravenously every 3 weeks;
3. Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle; Treatment consists of up to six 21-day cycles (induction phase), followed by sintilimab monotherapy maintenance until disease progression (PD), intolerable toxicity, investigator/patient decision to withdraw, or completion of 2 years total treatment (whichever occurs first). Tumor response will be assessed by MRI every two cycles during induction and quarterly thereafter
Orelabrutinib
Orelabrutinib: 150 mg orally once daily
Sintilimab
Sintilimab: 200 mg intravenously every 3 weeks
Temozolomide (TMZ)
Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orelabrutinib
Orelabrutinib: 150 mg orally once daily
Sintilimab
Sintilimab: 200 mg intravenously every 3 weeks
Temozolomide (TMZ)
Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Relapsed or refractory disease with at least 1 prior methotrexate-based therapy
3. Participant must be able to understand and willing to sign a written informed consent document.
4. Participant must have signed and dated written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
5. Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
6. Participant must be at least 18 years old on day of signing informed consent.
7. PCNSL subjects should have evidence of measurable or evaluable enhancing disease on MRI
8. Able to submit at least 10 but up to 20 unstained formalin-fixed, paraffin-embedded (FFPE) slides from the initial or most recent tissue diagnosis for correlative studies. Histologically confirmed tissue will be required from the time of relapse or at the time of initial surgery. If tissue is unavailable and/or diagnosis was made from cerebrospinal fluid or vitreal biopsy, approval from the overall principal investigator is needed.
9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.
10. Life expectancy of \>3 months (in the opinion of the investigator)
11. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1
12. Must be able to tolerate lumbar puncture and MRI/CT.
13. Demonstrate adequate organ function as defined below, all screening labs should be performed within 14 days of treatment initiation.
1. Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
2. Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 7 days prior to initiation of protocol treatment
3. Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR) \< 2 times the upper limit of normal
4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal
5. Serum bilirubin ≤ 1.5 times the upper limit of normal
6. Creatinine clearance \> 30 mL/min calculated by the Cockcroft-Gault formula using actual body weight
14. Women of child-bearing potential, must agree to use a highly effective method of contraception consistently and correctly as described below during study treatment and for 120 days after study discontinuation.
15. Male participants must agree to use at least one of the following methods of contraception starting with the first dose of study therapy through 120 days after the last dose of therapy:
16. Ability to swallow oral medications.
Exclusion Criteria
2. The pathological diagnosis was T-cell lymphoma.
3. Prior chemotherapy within 4 weeks or prior targeted small molecule therapy within 2 weeks , prior antibody-drug-conjugates within 10weeks, autologous stem cell transplant within 6 months, prior to the first day of study treatment, prior to the first day of study treatment.
4. Prior allogenic stem cell transplant.
5. Participation in another clinical study with an investigational product during the 4 weeks prior to the first day of study treatment.
6. External beam radiation therapy to the CNS within 14 days of the first day of study treatment.
7. Patient requires more than 8 mg of dexamethasone daily or the equivalent for control of CNS symptoms at the time of initiation of study therapy. Patients must taper off high dose corticosteroids for the control of CNS symptoms within 14 days after starting on study therapy.
8. History of intracranial hemorrhage or clinically significant stroke within 6 months prior to first day of study treatment
9. History of significant gastrointestinal disease that would limit absorption of oral medications.
10. Active concurrent malignancy requiring active therapy.
11. Prior therapy with a checkpoint inhibitor or BTK inhibitor.
12. Warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Use of low molecular weight heparin and novel oral anticoagulants (eg. rivaroxaban, apixaban) is permitted if required.
13. Concurrent use of a moderate or strong inhibitor or inducer of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers prior to starting the study drug.
14. Receipt of live attenuated vaccine within 30 days prior to the first day of study treatment. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last day of study treatment.
15. Suspicion of or confirmed progressive multifocal leukoencephalopathy
16. Active autoimmune disease (including autoimmune hemolytic anemia and immune thrombocytopenia purpura) requiring systemic treatment within the past two years (i.e. with the use of disease modifying agents, corticosteroids, or immunosuppressive drugs). The following are exceptions to this criterion:
1. Patients with vitiligo or alopecia
2. Patients with hypothyroidism (e.g., due to Hashimoto syndrome) stable on hormone replacement
3. Any chronic skin condition that does not require systemic therapy
4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician
5. Patients with celiac disease controlled by diet alone
6. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroids replacement therapy for adrenal or pituitary insufficiency, etc.)
17. Significant medical diseases or conditions, as assessed by the investigator, that would substantially increase the risk to benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction in the past 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, severely immunocompromised state, and congestive heart failure, New York Heart Association Class III-IV.
18. Known bleeding diathesis (e.g. von Willebrand's disease), hemophilia, or active bleeding.
19. Known Human immunodeficiency virus (HIV) infection.
20. Known active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests and/or PCR.
21. History of invasive fungal infection, including invasive aspergillosis, or known active tuberculosis.
22. Major surgery ≤ 6 weeks prior to starting the trial treatment (or has not recovered from the side effects of such surgery) or plans to have surgery within 2 weeks of the first dose of the study drug.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sir Run Run Shaw Hospital
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
Wenzhou Central Hospital
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Zhejiang Provincial Tongde Hospital
OTHER
First People's Hospital of Hangzhou
OTHER
Zhejiang Provincial People's Hospital
OTHER
Jinhua Central Hospital
OTHER
Jinhua People's Hospital
OTHER
Yinzhou Hospital Affiliated to Medical School of Ningbo University
OTHER
Huzhou Central Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I2021001524
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.